Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma


DOI
10.18632/oncotarget.24797

Publication date
2018

Document Version
Other version

Published in
Oncotarget

License
CC BY

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
## Supplementary Table 5A: References and characteristics of selected canonical FA/HR gene set variants in the tumor samples of the patients in the study

<table>
<thead>
<tr>
<th>Pts</th>
<th>Gene</th>
<th>Protein change</th>
<th>SNP ID</th>
<th>cosmic70 MAF</th>
<th>1000G MAF</th>
<th>CADD</th>
<th>REVEL</th>
<th>SIFT</th>
<th>PolyPhen2</th>
<th>ClinVar</th>
<th>Comments to potential functional effects</th>
<th>REF PMID</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PALB2</td>
<td>L337S</td>
<td>rs45494092</td>
<td>0.0249</td>
<td>8.918</td>
<td>0.041</td>
<td></td>
<td></td>
<td>B</td>
<td>Conflicting interpretations</td>
<td>Possibly enriched in familial cutaneous malignant melanoma. Similar frequency in breast cancer than controls.</td>
<td>24949998 21618343 26283626</td>
</tr>
<tr>
<td></td>
<td>FANCC</td>
<td>V60I</td>
<td>rs138629441</td>
<td>0.185</td>
<td>0.101</td>
<td></td>
<td></td>
<td>T</td>
<td>B</td>
<td>Likely benign (Fanconi Anemia)</td>
<td>Unlikely to affect function.</td>
<td>14695169</td>
</tr>
<tr>
<td></td>
<td>FANCG</td>
<td>R513Q</td>
<td>rs17885240</td>
<td>0.0129</td>
<td>15.01</td>
<td>0.016</td>
<td></td>
<td>T</td>
<td>B</td>
<td>Likely benign (Fanconi Anemia)</td>
<td>Increased frequency in children with AML.</td>
<td>16643430</td>
</tr>
<tr>
<td>2</td>
<td>PALB2</td>
<td>T1099R</td>
<td>rs142132127</td>
<td>16</td>
<td>0.214</td>
<td></td>
<td>Deleterious</td>
<td>Damaging</td>
<td>Uncertain significance</td>
<td>Semiconservative AS substitution in conserved 5th WD repeat, region of BRCA2, RAD51 and POLH interaction. Possible enrichment in individuals with breast or ovarian cancer.</td>
<td>25186627 26315354</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FANCG</td>
<td>R513Q</td>
<td>rs17885240</td>
<td>0.0129</td>
<td>15.01</td>
<td>0.016</td>
<td></td>
<td>T</td>
<td>B</td>
<td>Likely benign (Fanconi Anemia)</td>
<td>Unlikely to affect function.</td>
<td>14695169</td>
</tr>
<tr>
<td>3</td>
<td>PALB2</td>
<td>L337S</td>
<td>rs45494092</td>
<td>0.0249</td>
<td>8.918</td>
<td>0.041</td>
<td></td>
<td></td>
<td>B</td>
<td>Conflicting interpretations</td>
<td>Possibly enriched in familial cutaneous malignant melanoma. Similar frequency in breast cancer than controls.</td>
<td>see above</td>
</tr>
<tr>
<td></td>
<td>FANCG</td>
<td>R513Q</td>
<td>rs17885240</td>
<td>0.0129</td>
<td>15.01</td>
<td>0.016</td>
<td></td>
<td>T</td>
<td>B</td>
<td>Likely benign (Fanconi Anemia)</td>
<td>Unlikely to affect function.</td>
<td>see above</td>
</tr>
<tr>
<td>4</td>
<td>FANCG</td>
<td>R513Q</td>
<td>rs17885240</td>
<td>0.0129</td>
<td>15.01</td>
<td>0.016</td>
<td></td>
<td>T</td>
<td>B</td>
<td>Likely benign (Fanconi Anemia)</td>
<td>Unlikely to affect function.</td>
<td>see above</td>
</tr>
<tr>
<td>5</td>
<td>FANCM</td>
<td>K953N</td>
<td>rs142864437</td>
<td>14.93</td>
<td>0.085</td>
<td></td>
<td>Deleterious</td>
<td>Damaging</td>
<td>Uncertain significance</td>
<td>No reports found.</td>
<td>see above</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FANCA</td>
<td>A554V</td>
<td></td>
<td>19.95</td>
<td>0.636</td>
<td></td>
<td></td>
<td>T</td>
<td></td>
<td></td>
<td>No reports found.</td>
<td>see above</td>
</tr>
<tr>
<td>6</td>
<td>FANCM</td>
<td>T77A</td>
<td>rs61746895</td>
<td>0.0129</td>
<td>2.724</td>
<td>0.041</td>
<td></td>
<td>T</td>
<td>B</td>
<td>Likely benign (Fanconi Anemia)</td>
<td>Neighboring MPH1 (ERCC4-related helicase) region.</td>
<td>see above</td>
</tr>
<tr>
<td>7</td>
<td>FANCF</td>
<td>P320L</td>
<td>rs45451294</td>
<td>0.0119</td>
<td>16.83</td>
<td>0.096</td>
<td></td>
<td></td>
<td>T</td>
<td>Possibly Damaging (Fanconi Anemia)</td>
<td>Benign reported in one individual in controls in pancreatic cancer study.</td>
<td>see above</td>
</tr>
<tr>
<td></td>
<td>FANCF</td>
<td>R38H</td>
<td></td>
<td>23.2</td>
<td>0.14</td>
<td></td>
<td>Deleterious</td>
<td>Damaging</td>
<td>No reports found.</td>
<td>see above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>FANCF</td>
<td>P320L</td>
<td>rs45451294</td>
<td>0.0119</td>
<td>16.83</td>
<td>0.096</td>
<td></td>
<td></td>
<td>T</td>
<td>Possibly Damaging (Fanconi Anemia)</td>
<td>Benign reported in one individual in controls in pancreatic cancer study.</td>
<td>see above</td>
</tr>
<tr>
<td></td>
<td>FANCD2</td>
<td>N5455</td>
<td>rs145522204</td>
<td>0.0089</td>
<td>0.887</td>
<td>0.053</td>
<td></td>
<td>T</td>
<td>B</td>
<td>Benign</td>
<td>No reports found.</td>
<td>see above</td>
</tr>
<tr>
<td>9</td>
<td>FANCD2</td>
<td>R997Q</td>
<td></td>
<td>15.1</td>
<td>0.091</td>
<td></td>
<td></td>
<td>T</td>
<td>B</td>
<td>Non-conservative amino acid substitution in conserved region (ATPase domain)</td>
<td>Moderate frequency in breast / ovarian cancer.</td>
<td>see above</td>
</tr>
<tr>
<td>10</td>
<td>FANCC</td>
<td>H256R</td>
<td></td>
<td>16.51</td>
<td>0.058</td>
<td></td>
<td></td>
<td>T</td>
<td>B</td>
<td>Uncertain significance</td>
<td>Non-conservative amino acid substitution in conserved region (ATPase domain)</td>
<td>15695377</td>
</tr>
<tr>
<td>11</td>
<td>RAD51C</td>
<td>G264S</td>
<td>rs147241704</td>
<td>23</td>
<td>0.202</td>
<td></td>
<td></td>
<td></td>
<td>B</td>
<td>Uncertain significance</td>
<td>Increased frequency in breast / ovarian cancer. Moderate penetrance suggestion in ovarian cancer.</td>
<td>20400964 21990120</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>RAD51B</td>
<td>K243R</td>
<td>rs34594234</td>
<td>0.0089</td>
<td>25.4</td>
<td>0.186</td>
<td>T</td>
<td>Damaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>BRCA1</td>
<td>R841W</td>
<td>rs1800709</td>
<td>0.005</td>
<td>5.12</td>
<td>0.355</td>
<td>Deleterious</td>
<td>Possibly Damaging</td>
<td>Benign</td>
<td>(Hereditary Can)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Abbreviations and listing as in Supplementary Table 4.